Our sector specialties include: Consumer; Healthcare; Media; Power & Energy Transition; and Technology. Guggenheim Equity Research analysts average 18 years of Wall Street and industry experience, bringing our clients rich perspectives and deep domain expertise.
Rigorous primary research is central to our approach. Innovation and disruption are constants in the sectors we cover and on-the-ground work keeps our team at the leading edge of trend changes for the benefit of our clients. Our signature research products uncover these findings and include:
The Consumer team covers automotive, e-commerce, hardline and softline retail, and restaurants.
The Healthcare team covers biotechnology, biopharmaceuticals, diagnostics and life sciences tools, and healthcare services.
The Power & Energy Transition team covers energy & industrial technology, power, and utilities.
For access to our research offerings and products, please contact your Guggenheim Securities Sales representative or email GSInfo@guggenheimpartners.com.
Already Registered? View the content library on the research portal (login required).
I&I Spotlight Series – Treg-based Therapies
Senior Managing Directors Whitney Wolfe and Yatin Suneja partake in a Q&A session regarding the future of the Treg-Therapies.
Highlights From the Second Guggenheim Targeted Protein Day
Senior Managing Director Michael Schmidt discusses the key topics from the event.
| Date | Sector | Location | Conference Name |
|---|---|---|---|
| 2/23-2/26 | Healthcare | Telluride | Healthy Altitudes Summit |
| 6/23-6/26 | Healthcare | Boston | BioFrontier Bus Tour |
Wall Street Journal Highlights Michael Morris's Research About Media Consolidation
The Wall Street Journal’s Dan Gallagher highlighted the research of Media & Internet Equity Research Analyst Michael Morris regarding the recent announcement of one of the largest media consolidation transactions of all-time. Morris provided analysis of the deal’s potential implications for shareholders of the world's largest streaming service.
Biotech Research Analysts Publish Peer-Reviewed Article in Nature Reviews Drug Discovery
Guggenheim Securities Biotechnology Equity Research Analysts Yatin Suneja and Maddalena Delma Caiati, MD PhD are co-authors of the review, “Roads and detours for CAR T cell therapy in autoimmune diseases,” recently published in Nature Reviews Drug Discovery, one of the most influential, high-impact peer-reviewed journals in drug discovery and development.
Seamus Fernandez Joins CNBC to Discuss the Battle for Market Share in the Weight Loss Drug Industry
Global Biopharmaceutical and Biotechnology Equity Research Analyst Seamus Fernandez recently joined CNBC's "Power Lunch" to discuss his outlook for the two leading companies battling for market share in the weight loss drug industry.
